Exogene
- Biotech or pharma, therapeutic R&D
Exogene develops novel trispecific T cell engagers (TriTCEs) to tackle advanced solid tumors, using a combination of generative AI and a proprietary yeast display technology for T-cell receptor (TCR) binder discovery.
Exogene's TriTCEs have three unique attributes:
- Enhanced therapeutic window by engaging highly cancer-specific targets (peptide-HLAs) that are absent on healthy cells
- Enhanced tumor killing in immunosuppressive tumor microenvironment by engaging both CD3 and co-stimulatory receptor on T cells
- Enhanced serum half-life for weekly dosing
NO SERVICE PROVIDERS MEETINGS.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}